ESPERION THERAPEUTICS, INC.
ESPR US29664W1053
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -82% | 20% | -49% | -25% | -0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Koenig Sheldon L. CEO |
2.79 USD |
28,427 Sold |
79,254 USD |
17/09/2025 | 17/09/2025 |
| Looker Benjamin SR OFF |
2.80 USD |
6,267 Sold |
17,573 USD |
17/09/2025 | 17/09/2025 |
| Halladay Benjamin CFO |
2.81 USD |
7,046 Sold |
19,785 USD |
17/09/2025 | 17/09/2025 |
| Looker Benjamin SR OFF |
1.13 USD |
1,304 Sold |
1,470 USD |
17/07/2025 | 17/07/2025 |
| Halladay Benjamin CFO |
1.12 USD |
11 Sold |
12 USD |
17/07/2025 | 17/07/2025 |
| Koenig Sheldon L. CEO |
1.11 USD |
30,474 Sold |
33,796 USD |
17/06/2025 | 17/06/2025 |
| Looker Benjamin SR OFF |
1.15 USD |
6,422 Sold |
7,398 USD |
17/06/2025 | 17/06/2025 |
| Looker Benjamin SR OFF |
1.15 USD |
6,422 Sold |
7,398 USD |
17/06/2025 | 17/06/2025 |
| Looker Benjamin SR OFF |
1.15 USD |
6,422 Sold |
7,398 USD |
17/06/2025 | 17/06/2025 |
| Koenig Sheldon L. CEO |
1.11 USD |
30,474 Sold |
33,796 USD |
17/06/2025 | 17/06/2025 |